# US 2012/0251509 A1 · Cell-based anti-cancer compositions and methods of making and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251509 A1
- Document ID: US20120251509A1
- Status: Published application
- Kind: A1
- Application number: 13/503,214
- Filed: 2010-10-22
- Published: 2012-10-04
- Earliest claimed: 2009-10-22
- Inventors: Scott A. Waldman; Adam E. Snook
- Web page: https://patentgrep.com/patent/US20120251509A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 14/70503: {Immunoglobulin superfamily}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/42: Cancer antigens
- C07K 16/18: against material from animals or humans
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Isolated pluralities of T cells which recognize at least one epitope of a mucosally restricted antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of a mucosally restricted antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of a mucosally restricted antigen and T cells comprising such nucleic acid molecules.

## Claims

### Claim at position 1

1-55. (canceled)

### Claim 56

An isolated plurality of T cells which recognize at least one epitope of a mucosally restricted antigen, wherein said T cells are derived from clonal expansion of T cells that are isolated from an individual and transformed with a nucleic acid molecule which encodes a mucosally restricted antigen-binding membrane-bound fusion protein, and wherein the mucosally restricted antigen is selected from the group consisting of guanylyl cyclase C, sucrase isomaltase, CDX1, CDX2, mammoglobin, and small breast epithelial mucin.

### Claim 57 (depends on 56)

The isolated plurality of T cells of claim 56 wherein the mucosally restricted antigen is guanylyl cyclase C.

### Claim 58 (depends on 56)

The isolated plurality of T cells of claim 56 wherein the mucosally restricted antigen-binding membrane-bound fusion protein encoded by the nucleic acid molecule comprises at least a functional antigen binding fragment of an antibody which recognizes at least one epitope of the mucosally restricted antigen.

### Claim 59 (depends on 58)

The isolated plurality of T cells of claim 58 wherein the mucosally restricted antigen is guanylyl cyclase C.

### Claim 60 (depends on 57)

A method of treating an individual who has been diagnosed with cancer that expresses guanylyl cyclase C comprising the step of administering to the individual an effective amount of composition of claim 57.

### Claim 61 (depends on 57)

A method of preventing cancer that expresses guanylyl cyclase C in an individual identified as being at an elevated risk of developing cancer of that expresses guanylyl cyclase C comprising the step of administering to the individual an effective amount of a composition of claim 57.

### Claim 62 (depends on 56)

A method of treating an individual who has been diagnosed with cancer of a mucosal tissue that expresses a mucosally restricted antigen selected from the group consisting to guanylyl cyclase C, sucrase isomaltase, CDX1, CDX2, mammoglobin, and small breast epithelial mucin, the method comprising the step of administering to the individual an effective amount of a composition of claim 56.

### Claim 63 (depends on 56)

A method of preventing cancer of a mucosal tissue in an individual identified as being at an elevated risk of developing cancer of a mucosal tissue that expresses a mucosally restricted antigen selected from the group consisting to guanylyl cyclase C, sucrase isomaltase, CDX1, CDX2, mammoglobin, and small breast epithelial mucin, the method comprising the step of administering to the individual an effective amount of composition of claim 56.

### Claim 64

A method of making a plurality of T cells that recognize at least one epitope of a mucosally restricted antigen, the method comprising the steps of:
a) isolating a sample from a cell donor that comprises at least one T cell; and
b) isolating a T cell from said sample and transforming said T cell with a nucleic acid sequence that encodes a mucosally restricted antigen-binding membrane-bound fusion protein, wherein upon expression the fusion protein is a membrane bound protein; and culturing said transformed T cell under conditions to promote its replication for a period sufficient to produce a plurality of T cells that recognize the mucosally restricted antigen, wherein the mucosally restricted antigen is selected from the group consisting of guanylyl cyclase C, sucrase isomaltase, CDX1, CDX2, mammoglobin, and small breast epithelial mucin.

### Claim 65 (depends on 64)

The method of claim 64 wherein the mucosally restricted antigen-binding membrane-bound fusion protein encoded by the nucleic acid molecule comprises at least a functional antigen binding fragment of an antibody which recognizes at least one epitope of the mucosally restricted antigen.

### Claim 66 (depends on 61)

The method of claim 61 wherein the nucleic acid sequence that encodes the mucosally restricted antigen-binding membrane-bound fusion protein is obtained by the steps of:
administering a vaccine that comprises at least one epitope of the mucosally restricted antigen or a nucleic acid encoding a protein that comprises at least one epitope of the mucosally restricted antigen the mucosally restricted antigen to an antibody gene donor, obtaining one or more B cells from the antibody gene donor, identifying either a B cell that produces an antibody which recognize at least one epitope of the mucosally restricted antigen or a hybrid cell derived from a B cell that produces antibodies which recognize at least one epitope of the mucosally restricted antigen, isolating from the B cell a nucleic acid sequence that encodes the antibody that recognizes at least one epitope of the mucosally restricted antigen, making a chimeric gene that encodes a functional fragment of the antibody that recognizes at least one epitope of the mucosally restricted antigen and a protein sequence that renders the fusion protein a membrane bound protein, and preparing an expression vector that comprises the chimeric gene.

### Claim 67 (depends on 64)

The method of claim 64 wherein the mucosally restricted antigen is guanylyl cyclase C.

### Claim 68

A nucleic acid molecule comprising a nucleotide sequence that encodes a mucosally restricted antigen-binding membrane-bound fusion protein, wherein the mucosally restricted antigen is selected from the group consisting of guanylyl cyclase C, sucrase isomaltase, CDX1, CDX2, mammoglobin, and small breast epithelial mucin.

### Claim 69 (depends on 68)

The nucleic acid molecule of claim 68 wherein the nucleotide sequence that encodes a mucosally restricted antigen-binding membrane-bound fusion protein comprises coding sequence for at least a functional fragment of an antibody which binds to at least one epitope of the mucosally restricted antigen and a portion which renders the fusion protein a membrane bound protein when the nucleotide sequence is expressed in a cell, said nucleotide sequence that encodes the mucosally restricted antigen-binding membrane-bound fusion protein is optionally operatively linked to regulatory elements.

### Claim 70 (depends on 67)

The nucleic acid molecule of claim 67 wherein the nucleic acid molecule is a plasmid or a viral genome.

### Claim 71 (depends on 67)

The nucleic acid molecule of claim 67 wherein the mucosally restricted antigen is guanylyl cyclase C.

### Claim 72 (depends on 71)

An isolated T cell comprising a nucleic acid molecule of claim 71.

### Claim 73 (depends on 67)

A isolated T cell comprising a nucleic acid molecule of claim 67.
